A Phase 2 Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL)

Trial Profile

A Phase 2 Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL)

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Nov 2016

At a glance

  • Drugs Brentuximab vedotin (Primary) ; Rituximab
  • Indications B cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; Post-transplant lymphoproliferative disorder
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Seattle Genetics
  • Most Recent Events

    • 19 Oct 2015 Data of DLBCL patients who received single agent ADCETRIS or in combination with Rituxan every three weeks were published in a Seattle Genetics media release.
    • 22 Jun 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 17 Jun 2015 Data of patients with diffuse large B-cell lymphoma from this study were presented at the 13th International Conference on Malignant Lymphoma, according to a Seattle Genetics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top